Trump's Upcoming Executive Order to Boost Ibogaine Research Sparks Interest

Want the full story?
Read the complete article at KVIA
AI Summary
President Trump is anticipated to sign an executive order soon that will promote further research into ibogaine, a psychedelic currently classified as a Schedule I controlled substance. While the order will not seek to change ibogaine's legal status, it aims to explore its potential in treating opioid withdrawal and mental health issues. Ibogaine, derived from a Central African plant, has gained attention for its effects on opioid cravings and conditions like PTSD, despite its risks of heart complications and nausea. High-profile advocates, including former Texas Governor Rick Perry, support its research.
Key Details: • Executive order expected to be signed in the coming days. • Ibogaine is currently a Schedule I controlled substance. • Research could focus on treating opioid withdrawal and mental health conditions. • Ibogaine treatment can cause side effects such as abnormal heart rhythms.